It has been well established that c‐MYC signaling is often associated with low MHC‐I expression on tumor cells, and c‐MYC downregulation enhances antitumor immune responses via lowering the expression of immunosuppressive molecules including CD47 and PD‐L1.[38, 39, 47] It is thus tempting to speculate a functional or physical interaction between AhR and c‐MYC in regulating MHC‐I expression and tumor immunogenicity. The gene discussed is AHR; the disease is neoplasm.